---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026337"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:14:11.733952+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Chief Business & Legal Officer Joseph Vittiglio resigns; COO Marc Blaustein gets retention bonus and expanded role

## Summary
- Joseph Vittiglio resigns as Chief Business and Legal Officer & Secretary, effective Dec 31, 2022.
- COO Marc Blaustein assumes business development and investor relations responsibilities after Vittiglio's departure.
- Blaustein receives a service-based cash bonus of $83,000, payable in two equal installments (Dec 2022, June 2023).
- Blaustein eligible for performance-based cash bonuses up to $332,000 tied to critical corporate objectives set by Compensation Committee.
- Service-based bonus repayment required if Blaustein leaves voluntarily (non-Good Reason) or is terminated for Cause before May 31, 2023 (first installment) or Dec 31, 2023 (second).

## SEC filing metadata
- accession: 0000950170-22-026337
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/fnch-20221212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026337
- JSON: https://secwatch.observer/filing/0000950170-22-026337.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026337.txt

## Key facts
- Executive change
  Marc Blaustein changed role as Chief Operating Officer at Finch Therapeutics Group, Inc..
  - Action: assumed additional responsibilities
  - Role: Chief Operating Officer
  source text: Additionally, on December 7, 2022, the Company entered into a Retention Bonus Agreement with Marc Blaustein, the Company’s Chief Operating Officer, who will also take over business development and investor relations responsibilities following Mr. Vittiglio’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm
- Executive change
  Joseph Vittiglio resigned as Chief Business and Legal Officer and Secretary at Finch Therapeutics Group, Inc..
  - Action: resigned
  - Role: Chief Business and Legal Officer and Secretary
  source text: On December 7, 2022, Joseph Vittiglio informed Finch Therapeutics Group, Inc. (the “Company”) of his resignation as the Company’s Chief Business and Legal Officer and Secretary, effective as of December 31, 2022, in order to pursue other professional opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.